RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aridis Pharmaceuticals - Stock

Aridis Pharmaceuticals Net Income 2024

Aridis Pharmaceuticals Net Income

-4.09 M USD

Ticker

ARDS

ISIN

US0403341045

WKN

A2N38H

In 2024, Aridis Pharmaceuticals's profit amounted to -4.09 M USD, a -228.57% increase from the 3.18 M USD profit recorded in the previous year.

The Aridis Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2028e-
2027e-
2026e4.4
2025e66.83
2024e-4.09
2023e3.18
2022-30.37
2021-46.32
2020-22.33
2019-29.68
2018-23.46
2017-27.45
2016-8.89
2015-8.2

Aridis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aridis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aridis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aridis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aridis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aridis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aridis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aridis Pharmaceuticals’s growth potential.

Aridis Pharmaceuticals Revenue, Profit, and EBIT History

DateAridis Pharmaceuticals RevenueAridis Pharmaceuticals EBITAridis Pharmaceuticals Net Income
2028e257.63 M undefined0 undefined0 undefined
2027e201.47 M undefined164.59 M undefined0 undefined
2026e132.77 M undefined96.61 M undefined4.4 M undefined
2025e77.44 M undefined40.38 M undefined66.83 M undefined
2024e7.75 M undefined-4.39 M undefined-4.09 M undefined
2023e21.83 M undefined5.71 M undefined3.18 M undefined
20223.09 M undefined-29.99 M undefined-30.37 M undefined
20211.54 M undefined-42.71 M undefined-46.32 M undefined
20201 M undefined-22.4 M undefined-22.33 M undefined
20191.02 M undefined-29.09 M undefined-29.68 M undefined
20182.76 M undefined-24.12 M undefined-23.46 M undefined
2017860,000 undefined-19.74 M undefined-27.45 M undefined
20162.27 M undefined-7.88 M undefined-8.89 M undefined
20152.86 M undefined-7.91 M undefined-8.2 M undefined

Aridis Pharmaceuticals stock margins

The Aridis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aridis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aridis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aridis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aridis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aridis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aridis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aridis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aridis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aridis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aridis Pharmaceuticals Margin History

Aridis Pharmaceuticals Gross marginAridis Pharmaceuticals Profit marginAridis Pharmaceuticals EBIT marginAridis Pharmaceuticals Profit margin
2028e-731.15 %0 %0 %
2027e-731.15 %81.69 %0 %
2026e-731.15 %72.76 %3.32 %
2025e-731.15 %52.14 %86.3 %
2024e-731.15 %-56.58 %-52.78 %
2023e-731.15 %26.17 %14.58 %
2022-731.15 %-970.33 %-982.56 %
2021-731.15 %-2,773.38 %-3,007.79 %
2020-731.15 %-2,240 %-2,233 %
2019-731.15 %-2,851.96 %-2,909.8 %
2018-731.15 %-873.91 %-850 %
2017100 %-2,295.35 %-3,191.86 %
201614.98 %-347.14 %-391.63 %
201524.83 %-276.57 %-286.71 %

Aridis Pharmaceuticals Aktienanalyse

What does Aridis Pharmaceuticals do?

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry. Aridis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Aridis Pharmaceuticals's Profit Margins

The profit margins of Aridis Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Aridis Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Aridis Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Aridis Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Aridis Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Aridis Pharmaceuticals Stock

How much profit has Aridis Pharmaceuticals made this year?

Aridis Pharmaceuticals has made -4.09 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -228.57% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Aridis Pharmaceuticals publish its earnings?

Aridis Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Aridis Pharmaceuticals?

The profits of Aridis Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Aridis Pharmaceuticals?

You can learn more about the earnings of Aridis Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Aridis Pharmaceuticals pay?

Over the past 12 months, Aridis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aridis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aridis Pharmaceuticals?

The current dividend yield of Aridis Pharmaceuticals is .

When does Aridis Pharmaceuticals pay dividends?

Aridis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aridis Pharmaceuticals?

Aridis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aridis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aridis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aridis Pharmaceuticals from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did Aridis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/18/2024.

What was the dividend of Aridis Pharmaceuticals in the year 2023?

In the year 2023, Aridis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aridis Pharmaceuticals pay out the dividend?

The dividends of Aridis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aridis Pharmaceuticals

Our stock analysis for Aridis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aridis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.